$ANAB News
Last published 1d ago
- 1d agoANABAnaptys Announces Participation in Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences:
- 3w agoANABJemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal CancerGlobeNewswireApproval based on AZUR-1 data showing significant proportion of participants with no detectable signs of cancer one year or more after treatment No disease recurrences reported among responders after median follow up of
- 1mo agoANABAnaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business UpdateGlobeNewswireJemperli global net sales of $644 million (£480 million) for the six months ended June 30, 2026, representing 34% year-over-year growthPositive interim results from the pivotal AZUR-1 trial of Jemperli in untreated
- 2mo agoANABAnaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireSAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Chris
- 3mo agoCNXUFAANABCVE+1A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes NextGlobeNewswireIssued on behalf of Conexeu Sciences Inc. As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (NASDAQ:CNXU)
- 6mo agoANABAnaptys Announces First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireCompleted spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations businessNow exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with VandaAnnounced appointment
- 6mo agoANABAnaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of DirectorsGlobeNewswireStrengthens Leadership Team and Board with additional business development, finance and royalty management expertise SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a company focused on
- 6mo agoANABAnaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual ConferenceGlobeNewswireSAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Daniel Faga,
- 6mo agoVNDAANABVanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM EvidencePR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled "Efficacy and Safety of...
- 6mo agoANABDelaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach ClaimGlobeNewswireRuling preserves current contracted royalty rates and rejects Tesaro's request for any royalty reductionTrial to adjudicate Anaptys' contract claims and right to seek reversion of Jemperli against Tesaro/GSK is scheduled
- 6mo agoANABAnaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial CollaborationsGlobeNewswireFocused on protecting and returning value of Jemperli and imsidolimab royalties to shareholdersLaunches with virtual model, including limited FTEs and minimal operating expenses, and approximately $140-$145 million in
- 7mo agoANABFirst Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private PlacementGlobeNewswireInclusive of $80 million in proceeds from private placement by leading investorsFirst Tracks Biotherapeutics to launch with $180 million in cash and two-year cash-runway SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) --
- 7mo agoANABTRAXAnaptys Announces $100 Million Stock Repurchase Plan and Provides a Business UpdateGlobeNewswireAnaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026Anaptys to manage the financial collaborations for Jemperli with GSK and imsidolimab with
- 7mo agoANABAnaptys Board of Directors Approves Spin-Off of First Tracks BiotherapeuticsGlobeNewswireBoard sets spin-off distribution date for First Tracks Biotherapeutics: expected to occur April 20, 2026, pre-marketStockholders will receive one share of First Tracks Bio common stock for every one share of AnaptysBio
- 8mo agoANABTRAXAnaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireSpin-off of biopharma operations into a public company to be called "First Tracks Biotherapeutics" on track for Q2 2026, potentially as early as late-AprilPhase 1b enrollment ongoing in celiac disease and trial cohort
- 8mo agoVNDAANABVanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular PsoriasisPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its...
- 9mo agoANABAnaptys Announces Participation at Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president
- 10mo agoANABAnaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiaryGlobeNewswireTrial to resolve all claims in the Anaptys and Tesaro/GSK dispute is scheduled for July 14-17, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company
- 10mo agoANABAnaptys to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president
- 11mo agoANABAnaptys Announces Participation in December Investor ConferencesGlobeNewswireSAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president
- 11mo agoANABAnaptys Announces $100 Million Stock Repurchase PlanGlobeNewswireSAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors
- 11mo agoANABAnaptys Initiates Litigation Against Tesaro, a GSK SubsidiaryGlobeNewswireSAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a Verified Complaint
- 1y agoANABAnaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative ColitisGlobeNewswireRosnilimab was safe and well tolerated with similar adverse event rates vs. placeboObserved expected pharmacology, including ~90% depletion of pathogenic T cells, however lack of adequate efficacy at Week 12 does not
- 1y agoANABAnaptys Announces Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireAnnounced intent to separate biopharma operations from substantial royalty assets by YE 2026Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on track for Nov./Dec.
- 1y agoANABAnaptys Announces Participation in November Investor ConferencesGlobeNewswireSAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president
- 1y agoANABAnaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral PresentationGlobeNewswireNew data reinforce rosnilimab's efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced therapy, including
- 1y agoANABAnaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025GlobeNewswireSAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that complete data from the
- 1y agoANABAnaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026GlobeNewswireDesigned to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunitiesUpon completion, the royalty management company will manage royalties and milestone pa
- 1y agoANABAnaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14GlobeNewswireSAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc.
- 1y agoANABAnaptys Announces Participation in September Investor ConferencesGlobeNewswireSAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president
- 1y agoANABAnaptys Announces Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireAnnounces positive data for rosnilimab, a pathogenic T cell depleter, through Week 38 from Phase 2b rheumatoid arthritis trialEnrollment completed for rosnilimab Phase 2 ulcerative colitis trial; Top-line data through
- 1y agoANABAnaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RAGlobeNewswireBest-in-disease profile with JAK-like efficacy and monthly (Q4W) dosing in both three-month placebo-controlled and six-month blinded treatment periodFavorable safety and tolerability, particularly when compared to
- 1y agoANABAnaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025GlobeNewswireSAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast
- 1y agoANABAnaptys Announces First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireAnnounced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the first week of
- 1y agoANABDSGNPSTXXERS+1Bright Peak Therapeutics Appoints John Schmid to its Board of DirectorsGlobeNewswireSAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer,
- 1y agoANABAnaptys Announces Stock Repurchase PlanGlobeNewswireSAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors
- 1y agoANABAnaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewswireAnnounced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 monthsFull clinical and translational data for
- 1y agoANABAnaptys Announces Participation in March Investor ConferencesGlobeNewswireSAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president
- 1y agoANABAnaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 MonthsGlobeNewswireAchieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placeboAchieved statistical significance on key secondary endpoints at Week 12 on
- 1y agoANABAnaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025GlobeNewswireSAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast
- 1y agoANABAnaptys to Present at the Guggenheim SMID Cap Biotech ConferenceGlobeNewswireSAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president
- 1y agoANABVNDAVanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R AntagonistGlobeNewswireImsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda expects to immediately begin preparing BLA and MAA applications for the US and EUAnaptys to receive $15 million
- 1y agoVNDAANABVanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R AntagonistPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, global license...
- 1y agoANABAnaptys to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president
- 1y agoANABAnaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic DermatitisGlobeNewswireANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be discontinuedAnticipate top-line Phase 2b data in rheumatoid arthritis in February 2025 for
- 2y agoANABAnaptys Announces Participation in November and December Investor ConferencesGlobeNewswireSAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president
- 2y agoANABAnaptys Announces Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswireTop-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024Top-line Phase 2b data anticipated for rosnilimab, our PD-1 agonist, in rheumatoid arthritis (RA) in February
- 2y agoANABAnaptys Announces Participation in September Investor ConferencesGlobeNewswireSAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president
- 2y agoANABAnaptys Announces Pricing of $100 Million Underwritten Registered Direct OfferingGlobeNewswireSAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the pricing of an
- 2y agoANABAnaptys Announces Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswireTop-line data expected in December 2024 after having completed enrollment for Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonistTop-line data accelerated and now anticipated in Q1 2025 for Phase